Jean-Charles Soria, Amgen SVP of oncology within global development

#ES­MO22: Am­gen spot­lights con­fir­ma­to­ry win for KRAS G12C play­er Lumakras in lung can­cer — but there's plen­ty more da­ta to come

PARIS — Am­gen came to Paris with a two-step plan to re­veal con­fir­ma­to­ry Code­Break 200 tri­al da­ta for its KRAS G12C drug Lumakras in non-small cell lung can­cer. Af­ter tip­ping its cards ahead of the con­fer­ence to stake a top-line claim — sans da­ta — on hit­ting the pri­ma­ry end­point for me­di­an pro­gres­sion-free sur­vival over do­c­etax­el at 12 months, we’re get­ting the ini­tial snap­shot that de­tails just how the com­par­i­son stacks up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.